Last reviewed · How we verify
anti-arrhythmia agents
Anti-arrhythmia agents work by regulating abnormal heart rhythms through various mechanisms, including blocking sodium channels, potassium channels, or calcium channels.
Anti-arrhythmia agents work by regulating abnormal heart rhythms through various mechanisms, including blocking sodium channels, potassium channels, or calcium channels. Used for Supraventricular tachycardia, Ventricular fibrillation, Atrial fibrillation.
At a glance
| Generic name | anti-arrhythmia agents |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Anti-arrhythmia agents |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
These drugs can slow the heart rate, prolong the time between heartbeats, or convert an abnormal heart rhythm back to a normal one. They can also help prevent the heart from beating too quickly or irregularly.
Approved indications
- Supraventricular tachycardia
- Ventricular fibrillation
- Atrial fibrillation
Common side effects
- QT interval prolongation
- Torsades de pointes
- Bradycardia
- Nausea
- Dizziness
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients (PHASE4)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-arrhythmia agents CI brief — competitive landscape report
- anti-arrhythmia agents updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI